Literature DB >> 16304392

CLL biology and prognosis.

Guillaume Dighiero1.   

Abstract

Chronic lymphocytic leukemia (CLL) follows an extremely variable course with survival ranging from months to decades. Recently, there has been major progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in CLL patients. In particular, the mutational profile of Ig genes and some cytogenetic abnormalities have been found to be important predictors of prognosis in CLL. However, this progress has raised new questions about the biology and prognosis of the disease, some of which are addressed here. Such questions include: 1) What is the role of the B-cell receptor (BCR) in CLL pathogenesis? 2) Is CLL one disease? 3) Is CLL an accumulative disease? 4) What is the normal counterpart of the CLL B lymphocyte? 5) Have the Rai and Binet staging systems become obsolete? 6) Which is the best surrogate for Ig mutational profiles?

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16304392     DOI: 10.1182/asheducation-2005.1.278

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  11 in total

1.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

2.  Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations.

Authors:  Eloisa Jantus-Lewintre; Elena Sarsotti; María José Terol; Isabel Benet; Javier García-Conde
Journal:  Clin Transl Oncol       Date:  2006-11       Impact factor: 3.405

3.  Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience.

Authors:  Eiman A Al Zaabi; Louis A Fernandez; Irene A Sadek; D Christie Riddell; Wenda L Greer
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

4.  Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients.

Authors:  Renee C Tschumper; Susan M Geyer; Megan E Campbell; Neil E Kay; Tait D Shanafelt; Clive S Zent; Grzegorz S Nowakowski; Timothy G Call; Gordon W Dewald; Diane F Jelinek
Journal:  J Clin Invest       Date:  2008-01       Impact factor: 14.808

5.  Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKCα subversion induces up-regulation of PKCβII expression in B lymphocytes.

Authors:  Rinako Nakagawa; Milica Vukovic; Anuradha Tarafdar; Emilio Cosimo; Karen Dunn; Alison M McCaig; Ailsa Holroyd; Fabienne McClanahan; Alan G Ramsay; John G Gribben; Alison M Michie
Journal:  Haematologica       Date:  2015-01-23       Impact factor: 9.941

6.  Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia.

Authors:  Francesco Maura; Giovanna Cutrona; Sonia Fabris; Monica Colombo; Giacomo Tuana; Luca Agnelli; Serena Matis; Marta Lionetti; Massimo Gentile; Anna Grazia Recchia; Francesco Di Raimondo; Caterina Musolino; Fiorella Ilariucci; Nicola Di Renzo; Emanuela Pesce; Stefano Molica; Massimo Federico; Agostino Cortelezzi; Fortunato Morabito; Manlio Ferrarini; Antonino Neri
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

7.  Cytokine Contents in Chronic Lymphocytic Leukemia: Association with ZAP70 Expression.

Authors:  Nilgün Işıksaçan; Suzan Çınar; Esin Aktaş Çetin; Melih Aktan; Günnur Deniz
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

8.  The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index.

Authors:  Carolina Muñoz-Novas; María Poza-Santaella; Isabel González-Gascón Y Marín; María Hernández-Sánchez; Ana-Eugenia Rodríguez-Vicente; María-Stefania Infante; Cecilia Heras; María-Ángeles Foncillas; Karen Marín; Jesús-María Hernández-Rivas; José-Ángel Hernández
Journal:  Biomed Res Int       Date:  2018-03-15       Impact factor: 3.411

9.  Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report.

Authors:  Isrid Sturm; Joachim Oertel; Stephan Oertel; Jörg Westermann; Antonio Pezzutto
Journal:  J Med Case Rep       Date:  2008-08-14

Review 10.  Protein kinase C in cellular transformation: a valid target for therapy?

Authors:  Anuradha Tarafdar; Alison M Michie
Journal:  Biochem Soc Trans       Date:  2014-12       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.